Newbury Pharmaceuticals AB (publ) (NEWBRY.ST)
SEK 3.42
(-2.29%)
SEK 3.42
(-2.29%)
| Breakdown | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Revenue | 36.82 Million | 10.26 Million | 5.51 Million | 2.82 Million |
| Cost of Revenue | 20.79 Million | 6.31 Million | 3.95 Million | 2.36 Million |
| Gross Profit | 16.03 Million | 3.94 Million | 1.56 Million | 460 Thousand |
| Operating Expenses | 30.11 Million | 21.16 Million | 13.94 Million | 6.08 Million |
| Selling, General and Administrative Expenses | - | - | - | 2.81 Million |
| Research and Development Expenses | - | - | - | - |
| Other Expenses | 30.11 Million | 21.16 Million | - | - |
| Cost and Expenses | 50.9 Million | 27.48 Million | 17.89 Million | 8.45 Million |
| Operating Income | -14.07 Million | -19.58 Million | -14.66 Million | -5.62 Million |
| Interest Expense | - | - | - | 35 Thousand |
| Income Tax Expense | -4000.00 | 156 Thousand | - | 99 Thousand |
| Earnings before Tax | -15.4 Million | -19.43 Million | -14.66 Million | -5.55 Million |
| Net Income | -15.4 Million | -19.43 Million | -14.66 Million | -5.55 Million |
| Earnings Per Share Basic | -0.72 | -1.00 | -0.75 | -0.35 |
| Earnings Per Share Diluted | -0.72 | -1.00 | -0.75 | -0.35 |
| Weighted Average Shares Outstanding | 21.41 Million | 19.52 Million | 19.52 Million | 15.67 Million |
| Weighted Average Shares Outstanding (Diluted) | 21.41 Million | 19.52 Million | 19.52 Million | 15.67 Million |
| Gross Margin | 0.44 | 0.38 | 0.28 | 0.16 |
| EBIT Margin | -0.34 | -1.77 | -2.48 | -1.74 |
| Profit Margin | -0.42 | -1.89 | -2.66 | -1.96 |
| EBITDA | -12.34 Million | -18.33 Million | -13.66 Million | -4.91 Million |
| Earnings Before Tax Margin | -0.38 | -1.91 | -2.66 | -1.99 |
| Breakdown | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 |
|---|---|---|---|---|---|---|
| Revenue | 21.12 Million | 1.38 Million | 3.13 Million | 11.18 Million | 10.26 Million | 2.82 Million |
| Cost of Revenue | 11.49 Million | 1.08 Million | 1.4 Million | 6.82 Million | 6.31 Million | 1.57 Million |
| Gross Profit | 9.63 Million | 306 Thousand | 1.73 Million | 4.36 Million | 3.94 Million | 1.25 Million |
| Operating Expenses | 7.73 Million | 8.6 Million | 6.31 Million | 7.46 Million | 21.16 Million | 3.67 Million |
| Selling, General and Administrative Expenses | - | - | - | - | - | - |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 7.73 Million | 8.6 Million | - | - | - | - |
| Cost and Expenses | 19.22 Million | 9.68 Million | 7.71 Million | 14.28 Million | 27.48 Million | 5.25 Million |
| Operating Income | 1.89 Million | -8.29 Million | -4.58 Million | -3.09 Million | -19.58 Million | -4.79 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -229 Thousand | - | 38 Thousand | 187 Thousand | 156 Thousand | 156 Thousand |
| Earnings before Tax | 1.5 Million | -8.65 Million | -4.92 Million | -3.33 Million | -19.43 Million | -4.75 Million |
| Net Income | 1.73 Million | -8.65 Million | -4.96 Million | -3.52 Million | -19.43 Million | -4.75 Million |
| Earnings Per Share Basic | 0.07 | -0.39 | -0.25 | -0.18 | - | -0.24 |
| Earnings Per Share Diluted | 0.07 | -0.39 | -0.25 | -0.18 | - | -0.24 |
| Weighted Average Shares Outstanding | 24.25 Million | 22.3 Million | 19.52 Million | 19.52 Million | 19.52 Million | 19.52 Million |
| Weighted Average Shares Outstanding (Diluted) | 24.25 Million | 22.3 Million | 19.52 Million | 19.52 Million | 19.52 Million | 19.52 Million |
| Gross Margin | 0.46 | 0.22 | 0.55 | 0.39 | 0.38 | 0.44 |
| EBIT Margin | 0.11 | -5.67 | -1.32 | -0.24 | - | -1.53 |
| Profit Margin | 0.08 | -6.25 | -1.58 | -0.32 | -1.89 | -1.68 |
| EBITDA | 2.4 Million | -7.86 Million | -4.14 Million | -2.73 Million | - | -4.31 Million |
| Earnings Before Tax Margin | 0.09 | -5.99 | -1.46 | -0.28 | -1.91 | -1.70 |
688305
VANTI
002720
JINDALSTEL
ANRGF
121600